Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

Brunner, Hermine; Foeldvari, Ivan; Alexeeva, Ekaterina; AKTAY AYAZ, Nuray; Calvo Penades, Inmaculada; KASAPÇOPUR, Özgür; Chasnyk, Vyacheslav; Hufnagel, Markus; Zuber, Zbigniew; Schulert, Grant; Ozen, Seza; Rakhimyanova, Adelina; Ramanan, Athimalaipet; Scott, Christiaan; Sozeri, Betul; Zholobova, Elena; Martin, Ruvie; Zhu, Xuan; Whelan, Sarah; Pricop, Luminita; Martini, Alberto; Lovell, Daniel; Ruperto, Nicolino

doi:10.1136/ard-2022-222849

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

Copy For Citation

Brunner H., Foeldvari I., Alexeeva E., AKTAY AYAZ N., Calvo Penades I., KASAPÇOPUR Ö., ...More

ANNALS OF THE RHEUMATIC DISEASES, vol.82, no.1, pp.154-160, 2022 (SCI-Expanded)

Publication Type: Article / Article
Volume: 82 Issue: 1
Publication Date: 2022
Doi Number: 10.1136/ard-2022-222849
Journal Name: ANNALS OF THE RHEUMATIC DISEASES
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
Page Numbers: pp.154-160
Keywords: arthritis, juvenile, arthritis, psoriatic, biological therapy
Istanbul University Affiliated: Yes

Abstract

Background Treatment options in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) are currently limited. This trial aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA with inadequate response to conventional therapy.